IRD
Opus Genetics, Inc.
Biotechnology
Market Cap$346M
5Y Perf.+309.2%
Compare Stocks
2 / 10Try these comparisons:
Stock Comparison
IRD vs REPL
Revenue, margins, valuation, and 5-year total return — side by side.
REPL
Replimune Group, Inc.
Biotechnology
Market Cap$266M
5Y Perf.-69.5%
IRD vs REPL — Key Financials
Market cap, revenue, margins, and valuation side-by-side.
| Company Snapshot | IRD | REPL |
|---|---|---|
| Industry | Biotechnology | Biotechnology |
| Market Cap | $346M | $266M |
| Revenue (TTM) | $15M | $0.00 |
| Net Income (TTM) | $-68M | $-315M |
| Gross Margin | 5.6% | — |
| Operating Margin | -445.4% | — |
| Total Debt | $0.00 | $76M |
| Cash & Equiv. | $30M | $111M |
IRD vs REPL — Long-Term Stock Performance
Price return indexed to 100 at period start. Dividends excluded.
IRD
REPL
| Stock | Sep 24 | May 26 | Return |
|---|---|---|---|
| Opus Genetics, Inc. (IRD) | 100 | 409.2 | +309.2% |
| Replimune Group, In… (REPL) | 100 | 30.5 | -69.5% |
Price return only. Dividends and distributions are not included.
Quick Verdict: IRD vs REPL
Each card shows where this stock fits in a portfolio — not just who wins on paper.
Bottom line: REPL leads in 4 of 6 categories, making it the strongest pick for growth and revenue expansion and profitability and margin quality. Opus Genetics, Inc. is the stronger pick specifically for recent price momentum and sentiment. As sector peers, any of these can serve as alternatives in the same allocation.
IRD
Opus Genetics, Inc.
The Long-Run Compounder
IRD is the clearest fit if your priority is long-term compounding.
- 315.5% 10Y total return vs REPL's -78.0%
- +425.5% vs REPL's -53.4%
Best for: long-term compounding
REPL
Replimune Group, Inc.
The Income Pick
REPL carries the broadest edge in this set and is the clearest fit for income & stability and growth exposure.
- beta 0.83
- EPS growth 5.2%
- Lower volatility, beta 0.83, Low D/E 18.3%, current ratio 7.95x
Best for: income & stability and growth exposure
See the full category breakdown
| Category | Winner | Why |
|---|---|---|
| Growth | REPL | -39.7% revenue growth vs IRD's -42.3% |
| Quality / Margins | REPL | 2.4% margin vs IRD's -466.1% |
| Stability / Safety | REPL | Beta 0.83 vs IRD's 1.13 |
| Dividends | Tie | Neither stock pays a meaningful dividend |
| Momentum (1Y) | IRD | +425.5% vs REPL's -53.4% |
| Efficiency (ROA) | REPL | -94.4% ROA vs IRD's -188.8% |
IRD vs REPL — Financial Metrics
Side-by-side numbers across 2 stocks — who leads on profitability, valuation, growth, and risk.
BEST OVERALLIRDLAGGINGREPL
REPLReplimune Group, Inc.
1leads
IRDOpus Genetics, Inc.
2leads
6 Total Categories
CATEGORYLEADERvs REPLMETRICS WON
Income & Cash FlowRevenue, margins, and cash flow strength
IRD1/1
Valuation MetricsMultiples, price ratios, and targets
Tied
—
Profitability & EfficiencyROE, ROIC, leverage, and quality scores
REPL5/7
Total Returns1Y, 3Y, 5Y total returns with dividends
IRD6/6
Risk & VolatilityBeta, volatility, and downside exposure
Tied
—
Analyst OutlookRatings, price targets, and dividends
—
—
Income & Cash Flow (Last 12 Months)
IRD leads this category, winning 1 of 1 comparable metric.
Income & Cash Flow (Last 12 Months)
IRD and REPL operate at a comparable scale, with $15M and $0 in trailing revenue.
| Metric | IRDOpus Genetics, In… | REPLReplimune Group, … |
|---|---|---|
| RevenueTrailing 12 months | $15M | $0 |
| EBITDAEarnings before interest/tax | -$65M | -$323M |
| Net IncomeAfter-tax profit | -$68M | -$315M |
| Free Cash FlowCash after capex | -$33M | -$283M |
| Gross MarginGross profit ÷ Revenue | +5.6% | — |
| Operating MarginEBIT ÷ Revenue | -4.5% | — |
| Net MarginNet income ÷ Revenue | -4.7% | — |
| FCF MarginFCF ÷ Revenue | -2.2% | — |
| Rev. Growth (YoY)Latest quarter vs prior year | -20.4% | — |
| EPS Growth (YoY)Latest quarter vs prior year | +13.8% | +2.5% |
IRD leads this category, winning 1 of 1 comparable metric.
Valuation Metrics
Evenly matched — IRD and REPL each lead in 1 of 2 comparable metrics.
Valuation Metrics
| Metric | IRDOpus Genetics, In… | REPLReplimune Group, … |
|---|---|---|
| Market CapShares × price | $346M | $266M |
| Enterprise ValueMkt cap + debt − cash | $316M | $231M |
| Trailing P/EPrice ÷ TTM EPS | -2.49x | -1.09x |
| Forward P/EPrice ÷ next-FY EPS est. | — | — |
| PEG RatioP/E ÷ EPS growth rate | — | — |
| EV / EBITDAEnterprise value multiple | — | — |
| Price / SalesMarket cap ÷ Revenue | 31.47x | — |
| Price / BookPrice ÷ Book value/share | 21.30x | 0.65x |
| Price / FCFMarket cap ÷ FCF | — | — |
Evenly matched — IRD and REPL each lead in 1 of 2 comparable metrics.
Profitability & Efficiency
REPL leads this category, winning 5 of 7 comparable metrics.
Profitability & Efficiency
REPL delivers a -149.5% return on equity — every $100 of shareholder capital generates $-150 in annual profit, vs $-11 for IRD. On the Piotroski fundamental quality scale (0–9), REPL scores 2/9 vs IRD's 1/9, reflecting mixed financial health.
| Metric | IRDOpus Genetics, In… | REPLReplimune Group, … |
|---|---|---|
| ROE (TTM)Return on equity | -11.4% | -149.5% |
| ROA (TTM)Return on assets | -188.8% | -94.4% |
| ROICReturn on invested capital | — | -51.9% |
| ROCEReturn on capital employed | -164.5% | -55.9% |
| Piotroski ScoreFundamental quality 0–9 | 1 | 2 |
| Debt / EquityFinancial leverage | — | 0.18x |
| Net DebtTotal debt minus cash | -$30M | -$35M |
| Cash & Equiv.Liquid assets | $30M | $111M |
| Total DebtShort + long-term debt | $0 | $76M |
| Interest CoverageEBIT ÷ Interest expense | -29.25x | -48.62x |
REPL leads this category, winning 5 of 7 comparable metrics.
Total Returns (Dividends Reinvested)
IRD leads this category, winning 6 of 6 comparable metrics.
Total Returns (Dividends Reinvested)
A $10,000 investment in IRD five years ago would be worth $41,550 today (with dividends reinvested), compared to $932 for REPL. Over the past 12 months, IRD leads with a +425.5% total return vs REPL's -53.4%. The 3-year compound annual growth rate (CAGR) favors IRD at 60.8% vs REPL's -43.0% — a key indicator of consistent wealth creation.
| Metric | IRDOpus Genetics, In… | REPLReplimune Group, … |
|---|---|---|
| YTD ReturnYear-to-date | +152.8% | -62.5% |
| 1-Year ReturnPast 12 months | +425.5% | -53.4% |
| 3-Year ReturnCumulative with dividends | +315.5% | -81.5% |
| 5-Year ReturnCumulative with dividends | +315.5% | -90.7% |
| 10-Year ReturnCumulative with dividends | +315.5% | -78.0% |
| CAGR (3Y)Annualised 3-year return | +60.8% | -43.0% |
IRD leads this category, winning 6 of 6 comparable metrics.
Risk & Volatility
Evenly matched — IRD and REPL each lead in 1 of 2 comparable metrics.
Risk & Volatility
REPL is the less volatile stock with a 0.83 beta — it tends to amplify market swings less than IRD's 1.13 beta. A beta below 1.0 means the stock typically moves less than the S&P 500. IRD currently trades 92.2% from its 52-week high vs REPL's 25.2% drawdown — a narrower gap to the peak suggests stronger recent price momentum.
| Metric | IRDOpus Genetics, In… | REPLReplimune Group, … |
|---|---|---|
| Beta (5Y)Sensitivity to S&P 500 | 1.13x | 0.83x |
| 52-Week HighHighest price in past year | $5.82 | $13.24 |
| 52-Week LowLowest price in past year | $0.90 | $1.50 |
| % of 52W HighCurrent price vs 52-week peak | +92.2% | +25.2% |
| RSI (14)Momentum oscillator 0–100 | 54.6 | 46.3 |
| Avg Volume (50D)Average daily shares traded | 861K | 5.6M |
Evenly matched — IRD and REPL each lead in 1 of 2 comparable metrics.
Analyst Outlook
Insufficient data to determine a leader in this category.
Analyst Outlook
Wall Street rates IRD as "Buy" and REPL as "Buy". Consensus price targets imply 274.3% upside for REPL (target: $13) vs 43.1% for IRD (target: $8).
| Metric | IRDOpus Genetics, In… | REPLReplimune Group, … |
|---|---|---|
| Analyst RatingConsensus buy/hold/sell | Buy | Buy |
| Price TargetConsensus 12-month target | $7.67 | $12.50 |
| # AnalystsCovering analysts | 6 | 15 |
| Dividend YieldAnnual dividend ÷ price | — | — |
| Dividend StreakConsecutive years of raises | — | — |
| Dividend / ShareAnnual DPS | — | — |
| Buyback YieldShare repurchases ÷ mkt cap | +0.0% | 0.0% |
Insufficient data to determine a leader in this category.
Key Takeaway
IRD leads in 2 of 6 categories (Income & Cash Flow, Total Returns). REPL leads in 1 (Profitability & Efficiency). 2 tied.
Best OverallOpus Genetics, Inc. (IRD)Leads 2 of 6 categories
Loading custom metrics...
IRD vs REPL: Frequently Asked Questions
8 questions · data-driven answers · updated daily
01Is IRD or REPL a better buy right now?
Analysts rate Opus Genetics, Inc.
(IRD) a "Buy" — based on 6 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.
02Which is the better long-term investment — IRD or REPL?
Over the past 5 years, Opus Genetics, Inc.
(IRD) delivered a total return of +315. 5%, compared to -90. 7% for Replimune Group, Inc. (REPL). Over 10 years, the gap is even starker: IRD returned +315. 5% versus REPL's -78. 0%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.
03Which is safer — IRD or REPL?
By beta (market sensitivity over 5 years), Replimune Group, Inc.
(REPL) is the lower-risk stock at 0. 83β versus Opus Genetics, Inc. 's 1. 13β — meaning IRD is approximately 35% more volatile than REPL relative to the S&P 500.
04Which is growing faster — IRD or REPL?
On earnings-per-share growth, the picture is similar: Replimune Group, Inc.
grew EPS 5. 2% year-over-year, compared to -367. 4% for Opus Genetics, Inc.. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.
05Which has better profit margins — IRD or REPL?
Replimune Group, Inc.
(REPL) is the more profitable company, earning 0. 0% net margin versus -523. 4% for Opus Genetics, Inc. — meaning it keeps 0. 0% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: REPL leads at 0. 0% versus -564. 7% for IRD. At the gross margin level — before operating expenses — IRD leads at 100. 0%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.
06Which pays a better dividend — IRD or REPL?
None of the stocks in this comparison currently pay a material dividend.
All are effectively zero-yield and should be held for capital appreciation rather than income.
07Is IRD or REPL better for a retirement portfolio?
For long-horizon retirement investors, Opus Genetics, Inc.
(IRD) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 1. 13), +315. 5% 10Y return). Both have compounded well over 10 years (IRD: +315. 5%, REPL: -78. 0%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.
08What are the main differences between IRD and REPL?
Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both.
These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.
Find Stocks Like These
Explore pre-built screens for each stock's profile, or build a custom screen to find stocks that outperform both.
You Might Also Compare
Based on how these companies actually compete and overlap — not just which sector they're filed under.